📊 VMD Key Takeaways
Is Viemed Healthcare, Inc.. (VMD) a Good Investment?
VIEMED demonstrates strong topline growth (20.5% YoY) with excellent gross margins (57.5%) and a fortress balance sheet (0.08x debt/equity), indicating operational strength in healthcare services. However, net income declined 2.9% YoY despite revenue expansion, signaling concerning margin compression and the company must improve operating leverage to justify its growth trajectory.
Why Buy Viemed Healthcare, Inc.. Stock? VMD Key Strengths
- Strong revenue growth of 20.5% YoY in healthcare services sector
- Exceptional gross margins at 57.5% demonstrating pricing power and operational efficiency
- Conservative capital structure with 0.08x debt/equity ratio and minimal leverage risk
- Positive operating cash flow of $51.9M providing financial flexibility
- Strong equity base of $141.5M with manageable liability position
VMD Stock Risks: Viemed Healthcare, Inc.. Investment Risks
- Net income declining 2.9% YoY despite 20.5% revenue growth indicates margin compression and operational leverage concerns
- Capital-intensive business model with $40M annual CapEx limiting free cash flow to only $11.9M (4.4% FCF margin)
- Modest operating margin of 8.5% and net margin of 5.5% typical for healthcare but vulnerable to cost pressures
- Limited liquidity with current ratio of 1.18x and modest cash position of $13.5M relative to $199.2M asset base
- Healthcare sector regulatory and reimbursement risks could impact sustained margin profiles
Key Metrics to Watch
- Operating margin trend and ability to convert revenue growth to profit growth
- Free cash flow generation and CapEx intensity sustainability
- Gross margin stability amid potential competitive or cost pressures
- Current ratio and cash position adequacy for operational needs
Viemed Healthcare, Inc.. (VMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 4.4% FCF margin may limit capital allocation flexibility.
VMD Profit Margin, ROE & Profitability Analysis
VMD vs Services Sector: How Viemed Healthcare, Inc.. Compares
How Viemed Healthcare, Inc.. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Viemed Healthcare, Inc.. Stock Overvalued? VMD Valuation Analysis 2026
Based on fundamental analysis, Viemed Healthcare, Inc.. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Viemed Healthcare, Inc.. Balance Sheet: VMD Debt, Cash & Liquidity
VMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Viemed Healthcare, Inc..'s revenue has grown significantly by 106% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.25 reflects profitable operations.
VMD Revenue Growth, EPS Growth & YoY Performance
VMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $58.0M | $3.5M | $0.09 |
| Q2 2025 | $55.0M | $1.5M | $0.04 |
| Q1 2025 | $50.6M | $1.6M | $0.04 |
| Q3 2024 | $49.4M | $2.9M | $0.07 |
| Q2 2024 | $43.3M | $1.5M | $0.04 |
| Q1 2024 | $39.6M | $1.5M | $0.04 |
| Q3 2023 | $35.8M | $967.0K | $0.03 |
| Q2 2023 | $33.3M | $967.0K | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Viemed Healthcare, Inc.. Dividends, Buybacks & Capital Allocation
VMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Viemed Healthcare, Inc.. (CIK: 0001729149)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VMD
What is the AI rating for VMD?
Viemed Healthcare, Inc.. (VMD) has an AI rating of BUY with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VMD's key strengths?
Claude: Strong revenue growth of 20.5% YoY in healthcare services sector. Exceptional gross margins at 57.5% demonstrating pricing power and operational efficiency.
What are the risks of investing in VMD?
Claude: Net income declining 2.9% YoY despite 20.5% revenue growth indicates margin compression and operational leverage concerns. Capital-intensive business model with $40M annual CapEx limiting free cash flow to only $11.9M (4.4% FCF margin).
What is VMD's revenue and growth?
Viemed Healthcare, Inc.. reported revenue of $270.3M.
Does VMD pay dividends?
Viemed Healthcare, Inc.. does not currently pay dividends.
Where can I find VMD SEC filings?
Official SEC filings for Viemed Healthcare, Inc.. (CIK: 0001729149) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VMD's EPS?
Viemed Healthcare, Inc.. has a diluted EPS of $0.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Viemed Healthcare, Inc.. has a BUY rating with 68% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is VMD stock overvalued or undervalued?
Valuation metrics for VMD: ROE of 10.6% (sector avg: 16%), net margin of 5.5% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy VMD stock in 2026?
Our dual AI analysis gives Viemed Healthcare, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VMD's free cash flow?
Viemed Healthcare, Inc..'s operating cash flow is $51.9M, with capital expenditures of $40.0M. FCF margin is 4.4%.
How does VMD compare to other Services stocks?
Vs Services sector averages: Net margin 5.5% (avg: 10%), ROE 10.6% (avg: 16%), current ratio 1.18 (avg: 1.5).